These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 9315536)

  • 1. Effect of Ca2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate.
    Phillips DR; Teng W; Arfsten A; Nannizzi-Alaimo L; White MM; Longhurst C; Shattil SJ; Randolph A; Jakubowski JA; Jennings LK; Scarborough RM
    Circulation; 1997 Sep; 96(5):1488-94. PubMed ID: 9315536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential effects of citrate versus PPACK anticoagulation on measured platelet inhibition by abciximab, eptifibatide and tirofiban.
    Kereiakes DJ; Lorenz T; Young JJ; Kukielka G; Mueller MN; Nanniazzi-Alaimo L; Phillips DR
    J Thromb Thrombolysis; 2001 Oct; 12(2):123-7. PubMed ID: 11729363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Ca2+ chelation on the platelet inhibitory ability of the GPIIb/IIIa antagonists abciximab, eptifibatide and tirofiban.
    Marciniak SJ; Jordan RE; Mascelli MA
    Thromb Haemost; 2001 Mar; 85(3):539-43. PubMed ID: 11307828
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical pharmacology of eptifibatide.
    Phillips DR; Scarborough RM
    Am J Cardiol; 1997 Aug; 80(4A):11B-20B. PubMed ID: 9291241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.
    Batchelor WB; Tolleson TR; Huang Y; Larsen RL; Mantell RM; Dillard P; Davidian M; Zhang D; Cantor WJ; Sketch MH; Ohman EM; Zidar JP; Gretler D; DiBattiste PM; Tcheng JE; Califf RM; Harrington RA
    Circulation; 2002 Sep; 106(12):1470-6. PubMed ID: 12234950
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency. Implications for assay methodology and comparison of different antagonists.
    Storey RF; Wilcox RG; Heptinstall S
    Circulation; 1998 Oct; 98(16):1616-21. PubMed ID: 9778326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: role of plasma calcium levels.
    Mousa SA; Bozarth JM; Forsythe MS; Slee A
    Cardiovasc Res; 2000 Sep; 47(4):819-26. PubMed ID: 10974231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of eptifibatide.
    Scarborough RM
    Am Heart J; 1999 Dec; 138(6 Pt 1):1093-104. PubMed ID: 10577440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of extra- and intracellular calcium chelation on human platelet function and glycoprotein IIb-IIIa complex stability.
    Lanza F; Stierlé A; Gachet C; Cazenave JP
    Nouv Rev Fr Hematol (1978); 1992; 34(1):123-31. PubMed ID: 1523093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Porcine von Willebrand factor binding to human platelet GPIb induces transmembrane calcium influx.
    Mazzucato M; De Marco L; Pradella P; Masotti A; Pareti FI
    Thromb Haemost; 1996 Apr; 75(4):655-60. PubMed ID: 8743195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of glycoprotein IIIa PIA 1/A2 polymorphism on the PFA-100 response to GP IIb IIa receptor inhibitors-the importance of anticoagulants used.
    Aalto-Setälä K; Karhunen PJ; Mikkelsson J; Niemelä K
    J Thromb Thrombolysis; 2005 Aug; 20(1):57-63. PubMed ID: 16133898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmentation of inhibitory effects of glycoprotein IIb-IIIa antagonists in patients with diabetes.
    Keating FK; Whitaker DA; Sobel BE; Schneider DJ
    Thromb Res; 2004; 113(1):27-34. PubMed ID: 15081562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamics and pharmacokinetics of eptifibatide in patients with acute coronary syndromes: prospective analysis from PURSUIT.
    Tardiff BE; Jennings LK; Harrington RA; Gretler D; Potthoff RF; Vorchheimer DA; Eisenberg PR; Lincoff AM; Labinaz M; Joseph DM; McDougal MF; Kleiman NS;
    Circulation; 2001 Jul; 104(4):399-405. PubMed ID: 11468200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential inhibitory effects of platelet glycoprotein IIb/IIIa antagonists on aggregation induced by procoagulant agonists.
    Ilveskero S; Lassila R
    Thromb Res; 2006; 117(3):291-7. PubMed ID: 15878612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design and methodology of the PURSUIT trial: evaluating eptifibatide for acute ischemic coronary syndromes. Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy.
    Harrington RA
    Am J Cardiol; 1997 Aug; 80(4A):34B-38B. PubMed ID: 9291244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nonimmunogenicity of eptifibatide, a cyclic heptapeptide inhibitor of platelet glycoprotein IIb-IIIa.
    Lorenz TJ; Macdonald F; Kitt MM
    Clin Ther; 1999 Jan; 21(1):128-37. PubMed ID: 10090430
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of platelet glycoprotein IIb-IIIa number and glycoprotein IIIa Leu33Pro polymorphism on platelet aggregation and sensitivity to glycoprotein IIb-IIIa antagonists.
    Sirotkina OV; Khaspekova SG; Zabotina AM; Shimanova YV; Mazurov AV
    Platelets; 2007 Nov; 18(7):506-14. PubMed ID: 17957566
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy of fibrinogen and platelet supplementation on the in vitro reversibility of competitive glycoprotein IIb/IIIa (alphaIIb/beta3) receptor-directed platelet inhibition.
    Li YF; Spencer FA; Becker RC
    Am Heart J; 2001 Aug; 142(2):204-10. PubMed ID: 11479455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation.
    Nannizzi-Alaimo L; Alves VL; Phillips DR
    Circulation; 2003 Mar; 107(8):1123-8. PubMed ID: 12615789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glycoprotein IIb-IIIa content and platelet aggregation in healthy volunteers and patients with acute coronary syndrome.
    Yakushkin VV; Zyuryaev IT; Khaspekova SG; Sirotkina OV; Ruda MY; Mazurov AV
    Platelets; 2011; 22(4):243-51. PubMed ID: 21329420
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.